For women at high risk of OHSS who are undergoing ovarian stimulation in a GnRH agonist protocol, metformin may reduce the incidence of OHSS, however there is insufficient evidence to support its use in GnRH antagonist or PPOS cycles. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.